Immunodiagnosis - the promise of personalized immunotherapy

Front Immunol. 2023 Jul 13:14:1216901. doi: 10.3389/fimmu.2023.1216901. eCollection 2023.

Abstract

Immunotherapy showed remarkable efficacy in several cancer types. However, the majority of patients do not benefit from immunotherapy. Evaluating tumor heterogeneity and immune status before treatment is key to identifying patients that are more likely to respond to immunotherapy. Demographic characteristics (such as sex, age, and race), immune status, and specific biomarkers all contribute to response to immunotherapy. A comprehensive immunodiagnostic model integrating all these three dimensions by artificial intelligence would provide valuable information for predicting treatment response. Here, we coined the term "immunodiagnosis" to describe the blueprint of the immunodiagnostic model. We illustrated the features that should be included in immunodiagnostic model and the strategy of constructing the immunodiagnostic model. Lastly, we discussed the incorporation of this immunodiagnosis model in clinical practice in hopes of improving the prognosis of tumor immunotherapy.

Keywords: cancer; immunodiagnosis; immunotherapy; personalized therapy; precision medicine.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Artificial Intelligence*
  • Humans
  • Immunologic Tests
  • Immunotherapy / methods
  • Neoplasms* / diagnosis
  • Neoplasms* / therapy
  • Prognosis

Grants and funding

This work was supported by the National Natural Science Foundation of China (81672085); The Hubei Provincial Natural Science Foundation of China (2019CFA062); Reproductive Health Fund of Huiling Stem Cell Innovation Institute (FIRMSCOV05); Gynecological tumor special research Fund of Beijing Kanghua Traditional Chinese and Western Medicine Development Foundation (KH-2021-LLZX-074); National Medical Professional Postgraduate Education Steering Committee research topic (B2-YX20190502-01); Open Fund of State Key Laboratory of Reproductive Medicine (SKLRM-K201802).